{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"150"}],"title":"Relapsed (event)"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}],"title":"Died (event)"},{"measurements":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"131"}],"title":"Censored, follow-up ended at the time of Primary Completion Date"},{"measurements":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"149"}],"title":"Censored, follow-up ongoing at the time of Primary Completion Date"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"432"}],"units":"Participants"}],"description":"Distant metastasis-free survival (DMFS) was defined as the time from randomization to the first occurrence of distant metastasis or death, whichever occurred first, if death preceded documented recurrence. Patients who remained alive and free of distant metastasis were censored at the date of their last assessment.","groups":[{"description":"Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.","id":"OG000","title":"Dabrafenib and Trametinib Combination Therapy"},{"description":"Subjects received matching placebos orally for 12 months","id":"OG001","title":"Dabrafenib and Trametinib Placebos"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-Treat (ITT) Population","reportingStatus":"POSTED","timeFrame":"Approximately 4 years","title":"Percentage of Participants With Distant Metastasis-free Survival (DMFS) Events","type":"SECONDARY","unitOfMeasure":"Participants"}